Biotech News
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Partnership brings first-in-class IL-15 receptor agonist immunotherapy to patients in Israel Israeli Ministry of Health grants approval for ANKTIVA® (nogapendekin alfa inbakicept) in combination with BCG for adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors
